Payers' dilemma: looming costs for chronic conditions.


Biotech products for chronic conditions will be coming with regularity in the next few years, and these represent both a clinical opportunity and a financial challenge for health plans. So far, few payers have figured out how to make such treatments available without breaking the bank. The challenges ahead and strategies for handling them.